image
Technology - Software - Application - NASDAQ - US
$ 0.0932
-17.2 %
$ 4.73 M
Market Cap
-0.24
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PET stock under the worst case scenario is HIDDEN Compared to the current market price of 0.0932 USD, Wag! Group Co. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PET stock under the base case scenario is HIDDEN Compared to the current market price of 0.0932 USD, Wag! Group Co. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PET stock under the best case scenario is HIDDEN Compared to the current market price of 0.0932 USD, Wag! Group Co. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PET

image
$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4$0.3$0.3$0.2$0.2$0.1$0.1$0.0$0.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
70.5 M REVENUE
-15.98%
-10.4 M OPERATING INCOME
-104.69%
-17.6 M NET INCOME
-31.92%
-7 M OPERATING CASH FLOW
-8.32%
-1.96 M INVESTING CASH FLOW
84.01%
-3.73 M FINANCING CASH FLOW
-94.57%
15.4 M REVENUE
16.88%
-3.62 M OPERATING INCOME
18.14%
-4.81 M NET INCOME
23.12%
-1.73 M OPERATING CASH FLOW
46.85%
-567 K INVESTING CASH FLOW
-40.00%
-519 K FINANCING CASH FLOW
-18.09%
Balance Sheet Wag! Group Co.
image
Current Assets 15.1 M
Cash & Short-Term Investments 5.63 M
Receivables 6.58 M
Other Current Assets 2.86 M
Non-Current Assets 14.4 M
Long-Term Investments 0
PP&E 2.91 M
Other Non-Current Assets 11.5 M
19.12 %22.35 %9.70 %9.88 %38.94 %Total Assets$29.4m
Current Liabilities 29.5 M
Accounts Payable 6.17 M
Short-Term Debt 19.4 M
Other Current Liabilities 3.93 M
Non-Current Liabilities 464 K
Long-Term Debt 464 K
Other Non-Current Liabilities 0
20.61 %64.71 %13.13 %Total Liabilities$29.9m
EFFICIENCY
Earnings Waterfall Wag! Group Co.
image
Revenue 70.5 M
Cost Of Revenue 5.29 M
Gross Profit 65.2 M
Operating Expenses 75.6 M
Operating Income -10.4 M
Other Expenses 7.18 M
Net Income -17.6 M
80m80m70m70m60m60m50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)71m(5m)65m(76m)(10m)(7m)(18m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
92.50% GROSS MARGIN
92.50%
-14.73% OPERATING MARGIN
-14.73%
-24.92% NET MARGIN
-24.92%
3592.64% ROE
3592.64%
-59.68% ROA
-59.68%
-54.19% ROIC
-54.19%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Wag! Group Co.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)20212021Jul '21Jul '2120222022Jul '22Jul '2220232023Jul '23Jul '2320242024Jul '24Jul '2420252025
Net Income -17.6 M
Depreciation & Amortization 2.36 M
Capital Expenditures -1.83 M
Stock-Based Compensation 6.59 M
Change in Working Capital -2.1 M
Others 1.93 M
Free Cash Flow -8.84 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Wag! Group Co.
image
Wall Street analysts predict an average 1-year price target for PET of $2.75 , with forecasts ranging from a low of $0.5 to a high of $4 .
PET Lowest Price Target Wall Street Target
0.5 USD 436.48%
PET Average Price Target Wall Street Target
2.75 USD 2850.64%
PET Highest Price Target Wall Street Target
4 USD 4191.85%
Price
Max Price Target
Min Price Target
Average Price Target
444433332222111100Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Wag! Group Co.
image
Sold
0-3 MONTHS
56.8 K USD 8
3-6 MONTHS
27.4 K USD 8
6-9 MONTHS
273 K USD 8
9-12 MONTHS
893 K USD 8
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
234 K USD 1
6-9 MONTHS
1.48 M USD 2
9-12 MONTHS
7. News
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that on March 31, 2025 it has entered into a joint clinical study with Massachusetts General Hospital (MGH) scientists to validate a novel positron emission tomography (PET) imaging technique to monitor myelin integrity and demyelination in people with multiple sclerosis (MS). globenewswire.com - 1 month ago
Wag! Group Co. (PET) Q4 2024 Earnings Call Transcript Wag! Group Co. (NASDAQ:PET ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Greg Robles - IR Garrett Smallwood - Chairman & CEO Adam Storm - President & Chief Product Officer Alec Davidian - CFO Conference Call Participants Jeremy Hamblin - Craig-Hallum Operator Good morning, and welcome to the Wag! Fourth Quarter and Full-Year 2024 Earnings Conference Call. seekingalpha.com - 1 month ago
Wag! Reports Fourth Quarter and Full Year 2024 Results; Announces Review of Strategic Alternatives to Maximize Shareholder Value SAN FRANCISCO, March 24, 2025 (GLOBE NEWSWIRE) -- Wag! Group Co. (the “Company” or “Wag!”; Nasdaq: PET), which strives to be the number one platform to solve the service, product, and wellness needs of the modern U.S. pet household, today announced financial results for the fourth quarter and full year ended December 31, 2024. The Company also announced that its Board of Directors (the “Board”) is advancing its review of strategic alternatives to identify opportunities to maximize value for shareholders, including potential investments, strategic partnerships, sale, merger, or other strategic transactions involving the Company or its assets. globenewswire.com - 1 month ago
Wag! To Report Fourth Quarter and Full Year 2024 Financial Results on March 24, 2025 SAN FRANCISCO, March 18, 2025 (GLOBE NEWSWIRE) -- Wag! Group Co., (the “Company” or “Wag!”, Nasdaq: PET), which strives to be the number one platform to solve the service, product, and wellness needs of the modern U.S. pet household, today announced that it will report fourth quarter and full year 2024 financial results before market open on Monday, March 24, 2025. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. globenewswire.com - 1 month ago
Considering delayed non-dilutive sources of financing, CARBIOS postpones construction of its Longlaville PET biorecycling plant for 6 to 9 months Considering delayed non-dilutive sources of financing, CARBIOS postpones construction of its Longlaville PET biorecycling plant for 6 to 9 months globenewswire.com - 4 months ago
Origin Materials Continues Commercial Qualification, Announces Production of Caps with New Features WEST SACRAMENTO, Calif.--(BUSINESS WIRE)--Origin Materials (“Origin”) (NASDAQ: ORGN, ORGNW), a technology company with a mission to enable the world's transition to sustainable materials, today announced the production of PET caps with new features as commercial qualification continues. The latest caps were produced at our partner's facility in Germany on Origin's CapFormer System, its proprietary system for manufacturing recyclable PET closures. The caps, made with recycled PET and designed fo. businesswire.com - 4 months ago
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced dosing of the first cohort of patients in the PIPE-791 Phase 1b positron emission tomography (PET) tr. businesswire.com - 4 months ago
Wag! Group Co. (PET) Q3 2024 Earnings Call Transcript Wag! Group Co. (NASDAQ:PET ) Q3 2024 Results Conference Call November 13, 2024 8:30 AM ET Company Participants Greg Robles - Investor Relations Garrett Smallwood - Chief Executive Officer Adam Storm - President and Chief Product Officer Alec Davidian - Chief Financial Officer Conference Call Participants Ryan Meyers - Lake Street Capital Markets Jeremy Hamblin - Craig-Hallum Matthew Koranda - ROTH Capital Operator Good morning, and welcome to the Wag! Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 5 months ago
Wag! Group Co. (PET) Reports Q3 Loss, Lags Revenue Estimates Wag! Group Co. (PET) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.06 per share a year ago. zacks.com - 5 months ago
Wag! Reports Third Quarter 2024 Results SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Wag! Group Co. (the “Company” or “Wag!”; Nasdaq: PET), which strives to be the number one platform to solve the service, product, and wellness needs of the modern U.S. pet household, today announced financial results for the third quarter ended September 30, 2024. globenewswire.com - 5 months ago
PROUD PET PARENTS TEAM UP WITH GLOBAL SUPERSTAR MEGHAN TRAINOR AND FRESHPET TO SUPPORT ANIMAL SHELTERS Freshpet launches its first apparel collection in collaboration with the singer just in time for the holidays, with 100% of proceeds going to animal rescues BEDMINSTER, N.J. , Oct. 1, 2024 /PRNewswire/ -- Freshpet  (NYSE: FRPT) today launches its first-ever apparel collection with its global superstar partner Meghan Trainor in time for the holiday season. prnewswire.com - 7 months ago
GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease. businesswire.com - 7 months ago
8. Profile Summary

Wag! Group Co. PET

image
COUNTRY US
INDUSTRY Software - Application
MARKET CAP $ 4.73 M
Dividend Yield 0.00%
Description Wag! Group Co. develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. Its platform allows pet parents, who require specific pet care services, such as dog walking, pet sitting and boarding, advice from licensed pet experts, home visits, training, and access to other services. The company was founded in 2015 and is based in Purchase, New York.
Contact 2 Manhattanville Road, Purchase, NY, 10577 https://www.wagwalking.com
IPO Date Sept. 27, 2021
Employees 64
Officers Mr. Dylan Allread Chief Operating Officer Mr. Nicholas Yu Director of Legal & General Counsel Mr. Patrick McCarthy Chief Marketing Officer Mr. Adam Storm President & Chief Product Officer Mr. Mazi Arjomand Chief Technology Officer Mr. David Cane Chief Customer Officer Mr. Alec Davidian Chief Financial Officer Kimberly Hollinger Assistant Controller Mr. Garrett Smallwood Chairman & Chief Executive Officer